Navigation Links
Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Date:8/19/2007

International Clinical Data to be Presented at the 58th Annual Meeting of

the American Association for the Study of Liver Diseases (AASLD)

TAMPA, Fla., Aug. 15 /PRNewswire/ -- Romark Laboratories announced that it has initiated a phase II clinical trial of Alinia(R) (nitazoxanide) for treating chronic hepatitis C in the United States.

The clinical trial is designed to evaluate the effectiveness and safety of Alinia tablets administered in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) in 60 patients with chronic hepatitis C genotype 1 who have failed to respond to standard therapy (peginterferon and ribavirin). Pegasys and Copegus are being provided under a collaborative agreement between Romark and F. Hoffmann-La Roche Ltd.

"We are excited to be participating in this clinical trial," said David Nelson, M.D., Associate Professor of Medicine, Medical Director of Liver Transplantation, and Chief of the Hepatobiliary Disease Section at the University of Florida. "There is a critical need for new therapies for patients with hepatitis C, particularly those who have already failed existing therapies."

The company also announced that interim data from an international clinical trial in patients with chronic hepatitis C will be communicated at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in early November 2007.

"Initiation of the US study and communication of our international data represent important milestones for our development program," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark who invented nitazoxanide and is leading its clinical development. "We are enthusiastic about the results to be presented at the upcoming AASLD meeting and the opportunity to develop an important new treatment for patients suffering from chronic hepatitis C."

The company's STEALTH C (Studies to Evaluate Alinia for Treatment
'/>"/>

SOURCE Romark Laboratories, L.C.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. BioRobot MDx standardize your automated protocols in clinical laboratories
2. What patients want: A story of choice, clinical trials & evidence-based medicine
3. ZyStor seeks to raise $15M for clinical trials
4. Prodesse begins clinical trials for flu virus detection
5. ConjuGon raises $3.3 million to fund clinical trials
6. Cancer-fighting agent heads for clinical trials
7. Quintessence cancer treatment chosen for clinical studies
8. Third Wave reports clinical growth, continued loss
9. Childrens expanding use of Sunrise Clinical Manager
10. Life-sciences conference to feature novel research with clinical potential
11. $14 million grant to drive clinical research at UW
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... in mechanical engineering at the University of Texas at ... the North Texas section of the American Society of ... members in 158 countries who develop engineering standards and ... community, benefiting the world. , ASME recognized Baughn earlier ... honors banquet. Baughn retired as an engineering fellow in ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Automated cell ... and maintenance of cell culture. They allow production of ... needs of researchers in drug discovery and industries and ... in mAb production, iPSC research, cryobanking, cell-based assays, and ... contamination risk. , Analysts forecast the Global Cell ...
(Date:7/22/2014)... NJ (PRWEB) July 22, 2014 ... precision, portable, and mechanical balances and scales, proudly ... balances has won Laboratory Equipment magazine’s 2014 “Readers' ... the second consecutive year the Explorer was voted ... The annual Readers’ Choice Awards celebrates “excellence in ...
(Date:7/22/2014)... en SHENZHEN, China , 22 ... (BGI Tech), een dochtermaatschappij van BGI, ,s wereld grootste ... introductie aan van een nieuwe service ten behoeve van ... geavanceerde platform van Complete Genomics. In ... de sector in hoog aanzien staat vanwege de in ...
Breaking Biology Technology:UT Dallas professor receives Engineer of the Year award 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech introduceert service op gebied van hele menselijke exoomsequencing op geavanceerd Complete Genomics-platform 2
... (CTI),(Nasdaq and MTA: CTIC) announced today that the ... Letter") from the Listing,Qualifications Staff (the "Staff") of ... not comply with Marketplace Rule 4350(i)(1)(C) when the,Company ... ("SMI"),and issued additional common shares to SMI shareholders. ...
... 26 Cardium Therapeutics (NYSE Alternext US: CXM) today ... from the Company,s Board of Directors. The resignation ... "We thank Dr. Simon for his service to ... the years ahead," stated Christopher J. Reinhard, Chairman and ...
... Increased 2 Percent to $15.0 Billion; Fourth Quarter 2008 ... Per Share Increased 38 Percent to $3.90; Fourth Quarter ... $0.912009 Total Revenue Expected to be in the Range ... Expected to be in the Range of $4.55 to ...
Cached Biology Technology:Cell Therapeutics Receives Additional NASDAQ Notification 2Cell Therapeutics Receives Additional NASDAQ Notification 3Cell Therapeutics Receives Additional NASDAQ Notification 4Cardium Announces Retirement of Director 2Cardium Announces Retirement of Director 3Cardium Announces Retirement of Director 4Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 2Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 3Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 4Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 5Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 6Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 7Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 8Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 9Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 10Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 11Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 12Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 13Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 14Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 15Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 16Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 17Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 18Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 19Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 20Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 21Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 22Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 23Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 24Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 25Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 26Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 27
(Date:7/22/2014)... challenges faced by researchers in modifying properties of nanomaterials ... simple technique, thanks to recent innovative studies conducted by ... Through the use of a simple, efficient and low ... research teams, led by Professor Sow Chorng Haur from ... Science, demonstrated that the properties of two different types ...
(Date:7/22/2014)... of a multinational, collaborative effort, researchers from the Icahn ... over 100 locations in the human genome associated with ... study published on any psychiatric disorder to date, conducted ... Nature , point to biological mechanisms and pathways that ... to treating the disorder, which has seen little innovation ...
(Date:7/22/2014)... in schoolyards that feature natural habitats and trees and ... and inattention, according to a University of Colorado Boulder ... such settings also provide stress-reducing benefits for youth, according ... & Place. The study is one of the ... between student access to green settings and stress. , ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Mount Sinai scientists and international team shed new light on schizophrenia 2Mount Sinai scientists and international team shed new light on schizophrenia 3Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 2Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 3
... 8, 2010 -- Conversion of sorghum grass to ethanol ... at Iowa State University examined 12 varieties of sorghum grass ... designed to test the efficiency of double cropping sorghum grass ... author of the report, Ben Goff, found that using sorghum ...
... 10, 2010 -- To keep soldiers in the battlefield healthy, ... bacteria in water. Current techniques for analyzing water ... to complete, according to Bart Lipkens of Western New England ... in Andover, Ma. They are working on an ...
... garden next spring and farmers sow in their fields ... stay healthy, and grow to yield bountiful harvests. It,s a ... encourage seeds to germinate earlier in the season, resist insects ... are the topic of an article in the current issue ...
Cached Biology News:Growing sorghum for biofuel 2
... 1 ( Abpromise for all tested applications). ... to KLH derived from within residues 1850 to ... (Note: the amino acid sequence is proprietary) ... Entrez Gene ID: 89796 ...
Na+/H+ exchanger, isoform NHE1....
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Biology Products: